NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily

oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]

#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery

7 wks / oncodaily

Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory

1 month / endpoints / Andrew Dunn

Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 7 wks

Related Stories

Therapeutic HPV vaccine slows throat tumors in preclinical tests / 25 days
Gene‑editing trials explore one‑time fix for high cholesterol / 25 days
Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 4 wks
Eikon Therapeutics raises $381M IPO for cancer drug advancement / 4 wks
Aktis Oncology IPO boosts radiopharmaceutical pipeline / 2 months
Tumor bacteria drive head and neck immunotherapy resistance / 2 months
Carolyn Bertozzi Returns to Eli Lilly Board / 2 months

Related Tags

Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare

Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals

Eli Lilly

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

GLP‑1 drugs associated with lower addiction risk in large study (4 days)

Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial (13 days)

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.